Compare Alcon AG (ALC) vs Marqeta Inc (MQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Marqeta Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Marqeta Inc trades at $15.59 (market cap $1.77B). The key difference: Alcon AG is far larger — about 18.5× Marqeta Inc's market cap, and Alcon AG pays a 0.54% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| ALC | MQ | |
|---|---|---|
Market Cap | $32.69B | $1.77B |
Sector | Health | Technology |
52-Week High | $92.22 | $27.32 |
52-Week Low | $62.02 | $15.04 |
Enterprise Value | $36.28B | $1.07B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Marqeta (MQ) trades at $15.93, down 8.63% on the day, with a bullish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split effective July 1, 2026. Q1 2026 earnings beat expectations with EPS of $0.08 versus -$0.0136 forecast, though Q4 2025 missed. Revenue trends show recovery from 2024's $507M to $625M in 2025, with net income narrowing losses. Analyst consensus is a $19 price target with 32% buy ratings.
The outlook hinges on execution of European expansion and credit product growth, but high P/E of 420.88 reflects significant growth expectations. Risks include ongoing profitability challenges, competitive fintech pressure, and shareholder litigation. Institutional sentiment is cautiously optimistic given the price target upside, but the stock remains speculative until sustained profitability is achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
